| Entry |
|
| Name |
Drug metabolism - other enzymes - Drosophila sechellia
|
| Class |
Metabolism; Xenobiotics biodegradation and metabolism
 |
| Pathway map |
| Drug metabolism - other enzymes |

  |
| Organism |
Drosophila sechellia [GN: dse]
|
| Gene |
| | | GM23268 gene product from transcript GM23268-RA; K01951 GMP synthase (glutamine-hydrolysing) [EC: 6.3.5.2] [KO: K01951] [EC: 6.3.5.2] | | | | GM18051 gene product from transcript GM18051-RA; K01519 inosine triphosphate pyrophosphatase [EC: 3.6.1.19] [KO: K01519] [EC: 3.6.1.19] | | GM17296 gene product from transcript GM17296-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM17278 gene product from transcript GM17278-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM15739 gene product from transcript GM15739-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM23331 gene product from transcript GM23331-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM16333 gene product from transcript GM16333-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM23921 gene product from transcript GM23921-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM26122 gene product from transcript GM26122-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM26123 gene product from transcript GM26123-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM26124 gene product from transcript GM26124-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM26133 gene product from transcript GM26133-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM20028 gene product from transcript GM20028-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM11008 gene product from transcript GM11008-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM18614 gene product from transcript GM18614-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM17207 gene product from transcript GM17207-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM15740 gene product from transcript GM15740-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM15628 gene product from transcript GM15628-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM14898 gene product from transcript GM14898-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM12089 gene product from transcript GM12089-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM17209 gene product from transcript GM17209-RA; K00699 glucuronosyltransferase [EC: 2.4.1.17] [KO: K00699] [EC: 2.4.1.17] | | GM19850 gene product from transcript GM19850-RA; K01195 beta-glucuronidase [EC: 3.2.1.31] [KO: K01195] [EC: 3.2.1.31] | | GM16415 gene product from transcript GM16415-RA; K01195 beta-glucuronidase [EC: 3.2.1.31] [KO: K01195] [EC: 3.2.1.31] | | GM16857 gene product from transcript GM16857-RA; K01489 cytidine deaminase [EC: 3.5.4.5] [KO: K01489] [EC: 3.5.4.5] | | GM16858 gene product from transcript GM16858-RA; K01489 cytidine deaminase [EC: 3.5.4.5] [KO: K01489] [EC: 3.5.4.5] | | GM16862 gene product from transcript GM16862-RA; K01489 cytidine deaminase [EC: 3.5.4.5] [KO: K01489] [EC: 3.5.4.5] | | GM13670 gene product from transcript GM13670-RA; K00207 dihydropyrimidine dehydrogenase (NADP+) [EC: 1.3.1.2] [KO: K00207] [EC: 1.3.1.2] | | GM10816 gene product from transcript GM10816-RA; K01464 dihydropyrimidinase [EC: 3.5.2.2] [KO: K01464] [EC: 3.5.2.2] | | GM10462 gene product from transcript GM10462-RA; K01431 beta-ureidopropionase [EC: 3.5.1.6] [KO: K01431] [EC: 3.5.1.6] | | GM18176 gene product from transcript GM18176-RA; K00757 uridine phosphorylase [EC: 2.4.2.3] [KO: K00757] [EC: 2.4.2.3] | | GM15599 gene product from transcript GM15599-RA; K00757 uridine phosphorylase [EC: 2.4.2.3] [KO: K00757] [EC: 2.4.2.3] | | GM10155 gene product from transcript GM10155-RA; K00757 uridine phosphorylase [EC: 2.4.2.3] [KO: K00757] [EC: 2.4.2.3] | | GM26584 gene product from transcript GM26584-RA; K00876 uridine kinase [EC: 2.7.1.48] [KO: K00876] [EC: 2.7.1.48] | | GM21771 gene product from transcript GM21771-RA; K00876 uridine kinase [EC: 2.7.1.48] [KO: K00876] [EC: 2.7.1.48] | | |
|
| Compound |
| 6-Mercaptopurine | | 5-Fluorodeoxyuridine monophosphate | | 6-Thioinosine-5'-monophosphate | | Hydrazine | | Azathioprine | | Isoniazid | | Isonicotinic acid | | Acetylhydrazine | | N-Acetylisoniazid | | Thioguanine | | 5-FU | | SN-38 | | SN38 glucuronide | | 5-Fluorodeoxyuridine | | Capecitabine | | Tegafur | | 5'-Deoxy-5-fluorouridine | | APC | | NPC | | 6-Thiourate | | 6-Methylmercaptopurine | | 6-Methylthiopurine 5'-monophosphate ribonucleotide | | 6-Mercaptopurine ribonucleoside 5'-diphosphate | | 6-Mercaptopurine ribonucleoside triphosphate | | 6-Thioxanthine 5'-monophosphate | | 6-Thioguanosine monophosphate | | 6-Methylthioguanosine monophosphate | | 1-Methyl-4-nitroimidazole | | N,N'-Diacetylhydrazine | | Isonicotinylglycine | | Isoniazid pyruvate | | Isoniazid alpha-ketoglutaric acid | | 5,6-Dihydro-5-fluorouracil | | alpha-Fluoro-beta-ureidopropionic acid | | alpha-Fluoro-beta-alanine | | 5-Fluorouridine | | 5-Fluorouridine monophosphate | | 5'-Deoxy-5-fluorocytidine | | Irinotecan | | Azathioprine (JP16/USP/INN) | | Isoniazid (JP16/USP/INN) | | Fluorouracil (JP16/USP/INN) | | Capecitabine (JAN/USAN/INN) | | Tegafur (JP16/USAN/INN) | | Doxifluridine (JP16/INN) | | Floxuridine (USP/INN) | | Mercaptopurine (INN) | | Irinotecan (INN) | | Tioguanine (INN) |
|
| Reference |
|
| Authors |
Kato R, Kamatari T (eds). |
| Title |
[Drug Metabolism] (In Japanese) |
| Journal |
Tokyo Kagaku Dojin (2000) |
| Reference |
|
| Authors |
Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR. |
| Title |
Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. |
| Journal |
Dig Liver Dis 37:282-97 (2005) |
| Reference |
|
| Authors |
Gearry RB, Barclay ML. |
| Title |
Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. |
| Journal |
J Gastroenterol Hepatol 20:1149-57 (2005) |
| Reference |
|
| Authors |
Gilissen LP, Derijks LJ, Verhoeven HM, Bierau J, Hooymans PM, Hommes DW, Engels LG. |
| Title |
Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease. |
| Journal |
Dig Liver Dis 39:182-6 (2007) |
| Reference |
|
| Authors |
Fischel JL, Formento P, Ciccolini J, Etienne-Grimaldi MC, Milano G. |
| Title |
Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes. |
| Journal |
Anticancer Drugs 15:969-74 (2004) |
| Reference |
|
| Authors |
Shimma N, Umeda I, Arasaki M, Murasaki C, Masubuchi K, Kohchi Y, Miwa M, Ura M, Sawada N, Tahara H, Kuruma I, Horii I, Ishitsuka H. |
| Title |
The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. |
| Journal |
Bioorg Med Chem 8:1697-706 (2000) |
| Reference |
|
| Authors |
Chung YL, Troy H, Judson IR, Leek R, Leach MO, Stubbs M, Harris AL, Griffiths JR. |
| Title |
Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy. |
| Journal |
Clin Cancer Res 10:3863-70 (2004) |
| Reference |
|
| Authors |
Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. |
| Title |
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). |
| Journal |
Clin Cancer Res 7:2182-94 (2001) |
| Reference |
|
| Authors |
Kita T, Tanigawara Y, Chikazawa S, Hatanaka H, Sakaeda T, Komada F, Iwakawa S, Okumura K. |
| Title |
N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. |
| Journal |
Biol Pharm Bull 24:544-9 (2001) |
| KO pathway |
|